Post-RAI Therapy Dosimetry and Quality Assessment of Target Tissue Dosing

Launched by STATE UNIVERSITY OF NEW YORK - UPSTATE MEDICAL UNIVERSITY · Aug 31, 2023

Keywords

ClinConnect Summary

This study is watching how doctors measure the exact amount of radioactive iodine (I-131) that goes into the remaining thyroid tissue after treatment for well-differentiated thyroid cancer. Using a special scan called SPECT/CT and a dosimetry software, researchers hope to better map where residual disease is and estimate the radiation dose the tissue receives. They want to know if this imaging and dose information helps improve how the disease is staged (understood) and overall patient care after therapy.

Potential participants are adults 18 and older who have had total thyroid removal for differentiated thyroid cancer and have either local lymph node metastases or metastases in the chest/neck, lungs, or bones. About 10 people will be enrolled by invitation and followed for up to about two years. This is an observational study, not a test of a new drug, and involves collecting imaging and other data after standard post-treatment care at SUNY Upstate Medical University in Syracuse, NY.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All minorities
• • 18 years of age and older
• • Ability to give consent
• • Male or female
• • Differentiated thyroid cancer (DTC)
• • Previous total thyroidectomy
• * Has either:
• • local lymph node metastases
• • distant mediastinal/cervical metastases
• • lung or osseous metastases as seen on prior imaging studies
• Exclusion Criteria:
• • Non-iodine avid disease
• • Under 18 years of age
• • Unable to give consent
• • Pregnant women, Non-viable neonates or neonates of uncertain viability.
• • Non-English-speaking patients